Neumora Financial Results and Business Update

 On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024

Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026

https://www.biospace.com/article/releases/neumora-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update/